President and CEO
MD, Cornell Medical College, 1993, PhD, Molecular Biology, Cornell Graduate School of Medical Sciences, 1993, Current Role(s): President, Chief Executive Officer, Joined Syntrix: 2001
Dr. Zebala has led Syntrix from a basic research organization to a clinical-stage company. During his 10+ year tenure with the company, he was responsible for establishing company direction and bringing company drug assets into Phase 1 and Phase 2 clinical studies. Dr. Zebala was directly responsible for successfully authoring, submitting and opening Investigational New Drug (IND) applications with the FDA; navigating pre-IND and other post-IND Type B meetings with the FDA; designing and managing the toxicology studies that supported IND applications; directing the manufacture and supply of drug in compliance with current Good Manufacturing Practice; authoring and implementing Phase 1 and 2 clinical trial protocols and securing Institutional Review Board approval; securing National Institutes of Health (NIH) funding as Principal Investigator on over $20 million in grants to the company and $30 million in private financing; and securing deal discussions over these assets with several pharmaceutical companies. He is an inventor on over 20 issued or pending US patents, and author to more than 25 peer reviewed scientific articles. Dr. Zebala has served as an invited reviewer on numerous NIH study sections and review groups concerning drug development and therapeutics. He is the recipient of several research prizes and scientific awards including the David Roger Health Policy Colloquium Award from the Weill Cornell Medical College in 2011. Dr. Zebala was invited speaker at the National Cancer Institute investor forum at Boston University in 2009. Prior to joining Syntrix, Dr. Zebala developed foundational microarray technology for genomic analysis.